NEU²

new drugs
against
neurological diseases

 
 

MS Platform Labs (Fraunhofer IME Screening Port and inims)

The MS Platform Labs comprises two closely interacting laboratories, the biomarker laboratory at the inims (ZMNH) and the discovery biology laboratory located at the Fraunhofer IME ScreeningPort. The two main benefits of the MS Platform Labs are 1) appropriate standardization, for example validating MS-specific efficacy biomarkers can be used in a consistent and meaningful way for all NEU² projects, and 2) allowing streamlined implementation of generic activities, for example aggregating compounds for cell tox profiling studies to reduce costs and complexity. For both parts of the platform it is planned that further funding will derive from project-related activities under the NEU² projects.

The MS Platform Labs closely interacts with scientist at the inims, but also with investigators at the leading and sponsoring entities that pursue projects under NEU². Ideally, the biomarker and discovery biology platforms are used throughout the course of a project from very early stages to clinical testing.

NEU² – Biomarker platform (inims)

The biomarker lab of the MS Platform Labs pursues the following tasks:

  • Implementation of a robust biomarker profiling panel, with members identified by the biomarker platform
  • Small scale assay development in specific cellular or animal model systems in order to show and later validate activities of a specific drug/treatment approach
  • Profiling the mechanism of action (and also the potential adverse event potential) of a specific drug/treatment approach by broad-based techniques (genome-wide expression profiling, proteomics, metabolomics, regulomics) in a limited number of assays/conditions
  • Systems biology and systems pharmacology-based analysis of the data emerging from these assays
  • Analysis and benchmarking of the emerging data from diverse external sources including public and proprietary databases
  • Tailored testing of the respective approach in specific assay systems (focusing for example on the function of specific cell types such as T cells, B cells, monocytes, dendritic cells, neutrophils in the immune system and oligodendrocytes, neurons, astrocytes in the CNS context)
  • Search for and choice of potential biomarkers that can assist in dose finding, efficacy testing, in vivo confirmation of MOA and other aspects of preclinical and clinical testing
  • Responder/non-responder identification with the aid of suitable biomarkers

Sponsored by:

and supported by: